Advantages:
- Effectively decreases melanoma cell proliferation and suppresses tumor migration and metastasis.
- Promotes cancer cell death, specifically targeting melanoma cells and sparing healthy melanocytes.
- The method not only treats melanoma by targeting atypical PKC isoforms but also utilizes PKC-ι and PKC-ζ levels as biomarkers to predict treatment responsiveness, enhancing precision in therapy.
Summary:
Melanoma, a malignant tumor originating from melanocytes, becomes challenging to treat once it metastasizes, with current therapies offering limited success. Genetic mutations, particularly in the BRAF and CDKN2A genes, and overexpression of atypical PKC enzymes (PKC-ι and PKC-ζ), drive tumor progression and metastasis. Existing treatments targeting these pathways have limitations, highlighting the need for more effective therapies.
Our researchers developed a promising method for treating melanoma by targeting atypical protein kinase C (aPKC) isoforms, PKC-ι and PKC-ζ, using the inhibitors ICA-1 and ACPD. Their approach demonstrated a significant reduction in melanoma cell proliferation and increased apoptosis without harming normal melanocytes, highlighting its potential as a more effective and precise therapeutic option. This innovation addresses the limitations of existing melanoma treatments by offering a targeted therapy with dual functionality—both as a therapeutic intervention and a predictive diagnostic tool—enhancing treatment precision and effectiveness. This approach positions it as a potential breakthrough in personalized cancer treatment.
The image illustrates the cell proliferation of SK-MEL cells under varying concentrations of ICA-1 and ACPD, comparing their effects both in the absence and presence of these compounds.
Desired Partnerships:
- License
- Sponsored Research
- Co-Development